Drug Patents owned by Insmed Inc
1. List of Arikayce Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827317 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(10 months from now) | |
| US8802137 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(10 months from now) | |
| US7718189 | INSMED INC | Sustained release of antiinfectives |
Jun, 2025
(2 years from now) | |
| US8632804 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(3 years from now) | |
| US8642075 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(3 years from now) | |
| US8679532 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(3 years from now) | |
| US8226975 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Aug, 2028
(5 years from now) | |
| US9566234 | INSMED INC | Systems for treating pulmonary infections |
Jan, 2034
(10 years from now) | |
| US11446318 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US10751355 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US10251900 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US9895385 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a co...
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT family patents
73
United States
24
Japan
17
European Union
11
Spain
10
Canada
9
Australia
9
Korea, Republic of
7
Denmark
7
Portugal
6
Slovenia
6
Mexico
6
China
5
New Zealand
5
Poland
4
Israel
4
Cyprus
4
Hong Kong
4
Brazil
4
Lithuania
3
Croatia
3
Hungary
2
ME
2
Russia
2
RS
2
South Africa
1
Colombia
1
Ecuador
1
Honduras
1
Costa Rica
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic